Low serum paraoxonase1 activity levels predict coronary artery disease severity

Ting Sun, Jingchao Hu, Zhaofang Yin, Zuojun Xu, Liang Zhang, Li Fan, Yang Zhuo, Changqian Wang, Ting Sun, Jingchao Hu, Zhaofang Yin, Zuojun Xu, Liang Zhang, Li Fan, Yang Zhuo, Changqian Wang

Abstract

Paraoxonase1 (PON1) activity is closely related to coronary artery disease (CAD). However, whether PON1 activity can predict the degree of coronary stenosis remains unknown. In the present study, the serum PON1 activity and related factors that influence PON1 activity were analyzed in 186 patients with diagnostic coronary angiography. The serum PON1 activity was determined using a spectrophotometry-based assay in 186 patients with diagnostic coronary angiography, in which coronary stenosis severity was graded and clinically defined as single- or multi-vessel stenosis >50%. Target lesion stenosis was quantified via quantitative coronary angiography (QCA). The serum PON1 activity was significantly decreased in the CAD group, the multiple coronary stenosis subgroup, and the diabetes mellitus subgroup compared with each control group. The PON1 activity was positively correlated with the High density lipoprotein cholesterol (HDL-C) and Apolipoprotein A1 (ApoA1). Males, smoking, diabetes, and heart failure were identified as factors that influenced PON1 activity. Furthermore, a Receiver Operating Characteristic Curve (ROC) analysis indicated that a PON1 activity cut-off point of 330 U/L could predict CAD with a sensitivity of 52% and a specificity of 65%. In conclusion, low PON1 activity predicted the degree of coronary lesion, particularly in multiple vessel lesions, smokers, and diabetes, which may represent a biochemical marker for the severity of CAD.

Keywords: atherosclerosis; coronary artery disease; high-density lipoprotein cholesterol; paraoxonase1.

Conflict of interest statement

CONFLICTS OF INTEREST

There is no conflict of interest.

Figures

Figure 1. Association between serum PON1 activity…
Figure 1. Association between serum PON1 activity and clinical characteristics and lipid parameters
Figure 2. ROC curve analysis of serum…
Figure 2. ROC curve analysis of serum PON1 activity

References

    1. Hu G, Root M, Duncan AW. Adding multiple risk factors improves Framingham coronary heart disease risk scores. Vasc Health Risk Manag. 2014(10):557–562.
    1. De Backer GG. New risk markers for cardiovascular prevention. CurrAtheroscler Rep. 2014(16):427.
    1. Morgantini C, Meriwether D, Baldi S, Venturi E, Pinnola S, Wagner AC, Fogelman AM, Ferrannini E, Natali A, Reddy ST. HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. NutrMetab Cardiovasc Dis. 2014(24):594–599.
    1. Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014(371):2383–2393.
    1. Sinning C, Kieback A, Wild PS, Schnabel RB, Ojeda F, Appelbaum S, Zeller T, Lubos E, Schwedhelm E, Lackner KJ, Debus ES, Munzel T, Blankenberg S, et al. Association of multiple biomarkers and classical risk factors with early carotid atherosclerosis: results from the Gutenberg Health Study. Clin Res Cardiol. 2014(103):477–485.
    1. Tiozzo E, Gardener H, Hudson BI, Dong C, Della-Morte D, Crisby M, Goldberg RB, Elkind MS, Cheung YK, Wright CB, Sacco RL, Rundek T. High-density lipoprotein subfractions and carotid plaque: the Northern Manhattan Study. Atherosclerosis. 2014(237):163–168.
    1. Vakili L, Navab KD, Shabihkhani M, Pourtabatabaei N, Vazirian S, Barseghian Z, Seyedali S, Hough G. Systemic inflammation, intestine, and paraoxonase-1. AdvExp Med Biol. 2014(824):83–88.
    1. Eren E, Yilmaz N, Aydin O. Functionally defective high-density lipoprotein and paraoxonase: a couple for endothelial dysfunction in atherosclerosis. Cholesterol. 2013(2013):92090.
    1. Eren E, Ellidag HY, Aydin O, Yilmaz N. Homocysteine, Paraoxonase-1 and Vascular Endothelial Dysfunction: Omnibus viisRomamPervenitur. J ClinDiagn Res. 2014(8):CE01–4.
    1. Toth PP, Barylski M, Nikolic D, Rizzo M, Montalto G, Banach M. Should low high-density lipoprotein cholesterol (HDL-C) be treated? Best Pract Res ClinEndocrinolMetab. 2014(28):353–368.
    1. Shekhanawar M, Shekhanawar SM, Krisnaswamy D, Indumati V, Satishkumar D, Vijay V, Rajeshwari T, Amareshwar M. The role of ‘paraoxonase-1 activity’ as an antioxidant in coronary artery diseases. J ClinDiagn Res. 2013(7):1284–1287.
    1. Dullaart RP, Kwakernaak AJ, Dallinga-Thie GM. The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome. Atherosclerosis. 2013(230):6–11.
    1. Sagit M, Sarli B, Guler S, Namuslu M, Celik HT, Kurtul S, Korkmaz F, Somdas MA. Assessment of early atherosclerotic findings in patients with nasal polyposis. AurisNasus Larynx. 2014(41):179–184.
    1. Yunoki K, Naruko T, Inaba M, Inoue T, Nakagawa M, Sugioka K, Ohsawa M, Iwasa Y, Komatsu R, Itoh A, Haze K, Yoshiyama M, Becker AE, et al. Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease. Atherosclerosis. 2013(231):308–314.
    1. Krychtiuk KA, Kastl SP, Pfaffenberger S, Pongratz T, Hofbauer SL, Wonnerth A, Katsaros KM, Goliasch G, Gaspar L, Huber K, Maurer G, Dostal E, Oravec S, et al. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis. 2014;237:589–596.
    1. Maturu VN, Gupta N, Singh G, Gill K, Sharma YP, Singh S. Serum Paraoxonase (PON1) Activity in North-West Indian Punjabi's with Acute Myocardial Infarction. Indian J ClinBiochem. 2014(28):248–254.
    1. Jamuna Rani A, Mythili SV, Nagarajan S. Study on paraoxonase 1 in type 2 diabetes mellitus. Indian J PhysiolPharmacol. 2014(58):13–16.
    1. Nicholls SJ, Pisaniello AD, Kataoka Y, Puri R. Lipid pharmacotherapy for treatment of atherosclerosis. Expert OpinPharmacother. 2014(15):1119–1125.
    1. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, Miller JE, Boulton AJ, Durrington PN. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis. 1998;139:341–349.
    1. Haraguchi Y, Toh R, Hasokawa M, Nakajima H, Honjo T, Otsui K, Mori K, Miyamoto-Sasaki M, Shinohara M, Nishimura K, Ishida T, Hirata K. Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. Atherosclerosis. 2014(234):288–294.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅